Victory Capital Management Inc. Increases Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Victory Capital Management Inc. grew its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 677.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 237,250 shares of the biotechnology company’s stock after purchasing an additional 206,750 shares during the period. Victory Capital Management Inc. owned approximately 0.86% of AnaptysBio worth $7,948,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Frazier Life Sciences Management L.P. grew its position in AnaptysBio by 140.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after acquiring an additional 1,265,891 shares in the last quarter. Assenagon Asset Management S.A. raised its position in AnaptysBio by 55.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after purchasing an additional 168,813 shares during the period. Cubist Systematic Strategies LLC bought a new stake in AnaptysBio in the second quarter worth about $1,360,000. Renaissance Technologies LLC increased its position in shares of AnaptysBio by 52.4% during the second quarter. Renaissance Technologies LLC now owns 152,702 shares of the biotechnology company’s stock worth $3,827,000 after acquiring an additional 52,502 shares during the period. Finally, Ensign Peak Advisors Inc lifted its holdings in shares of AnaptysBio by 74.4% in the 2nd quarter. Ensign Peak Advisors Inc now owns 75,755 shares of the biotechnology company’s stock worth $1,898,000 after buying an additional 32,313 shares during the period.

Analysts Set New Price Targets

ANAB has been the topic of a number of analyst reports. JPMorgan Chase & Co. cut their price objective on shares of AnaptysBio from $75.00 to $66.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. Guggenheim raised their target price on AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Truist Financial boosted their price target on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Wedbush reissued an “outperform” rating and issued a $42.00 price objective on shares of AnaptysBio in a report on Thursday, November 14th. Finally, UBS Group raised their target price on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $54.64.

AnaptysBio Price Performance

Shares of ANAB stock opened at $21.24 on Friday. The company has a market capitalization of $646.42 million, a PE ratio of -3.49 and a beta of -0.24. The firm’s 50-day moving average is $30.12 and its two-hundred day moving average is $29.77. AnaptysBio, Inc. has a 12 month low of $13.36 and a 12 month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. Sell-side analysts forecast that AnaptysBio, Inc. will post -6.02 EPS for the current year.

Insider Transactions at AnaptysBio

In other news, insider Eric J. Loumeau sold 8,720 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.82, for a total value of $347,230.40. Following the completion of the transaction, the insider now owns 7,020 shares in the company, valued at approximately $279,536.40. This represents a 55.40 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares of the company’s stock, valued at $595,440.66. The trade was a 8.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,440 shares of company stock worth $892,936 over the last ninety days. Company insiders own 33.70% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.